Alimera Sciences (ALIM) 5.16 $ALIM
How it All Plays Out: Research Reports on Align Technology, Alimera, Alkermes, Alliance HealthCare Services, and Allied Healthcare Products
PR Newswire - Tue Feb 03, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Align Technology (NASDAQ: ALGN), Alimera (NASDAQ: ALIM), Alkermes (NASDAQ: ALKS), Alliance HealthCare Services, (NASDAQ: AIQ), and Allied Healthcare Products (NASDAQ: AHPI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ALGN: 56.90 (-0.34), ALIM: 5.16 (unch), AHPI: 1.56 (unch), ALKS: 71.40 (-1.89), AIQ: 24.99 (+0.27)
Alimera Sciences announces marketing approval for ILUVIEN in Finland and Luxembourg under Repeat-Use application procedure
M2 - Tue Jan 27, 3:32AM CST
Pharmaceutical company Alimera Sciences (NasdaqGM:ALIM) revealed on Monday the receipt of marketing authorisation in Finland and Luxembourg for ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.16 (unch)
Alimera Sciences' ILUVIEN® Receives Marketing Authorization in Finland and Luxembourg
PR Newswire - Mon Jan 26, 1:00PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that marketing authorization has been granted by the Finnish Medicines Agency in Finland and the Ministry of Health in Luxembourg to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.16 (unch)
Alimera Continues To Fly Under Radar As ILUVIEN Launch In U.S. Approaches
Gary Bourgeault - at Seeking Alpha - Sat Jan 17, 11:51AM CST
ALIM: 5.16 (unch)
Iluvien sales commence in Portugal
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 11:35AM CST
ALIM: 5.16 (unch), PSDV: 4.19 (+0.12)
Alimera Sciences Announces First Sale of ILUVIEN® in Portugal
PR Newswire - Wed Jan 14, 10:48AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals today announced that the first unit of ILUVIEN® has been sold in Portugal for the treatment of vision impairment associated with chronic diabetic macular edema insufficiently responsive to available treatments. Portugal is the third country in which ILUVIEN is now commercially available.
ALIM: 5.16 (unch)
NEA Names Frank Torti and Rick Yang Partners; Aaron Jacobson Promoted to Principal
PR Newswire - Tue Jan 13, 3:17PM CST
New Enterprise Associates, Inc. (NEA), a global venture capital firm, today announced the promotions of three members of its investing team: Frank Torti, M.D., to Partner; Rick Yang to Partner; and Aaron Jacobson to Principal.
ALIM: 5.16 (unch)
Insider Trading Alert - TESO, ALIM And NUAN Traded By Insiders
at The Street - Wed Jan 07, 10:45AM CST
Stocks with insider trader activity include TESO, ALIM and NUAN
ALIM: 5.16 (unch), NUAN: 14.26 (+0.20), TESO: 11.37 (+0.37)
Alimera Sciences Added to NASDAQ Biotechnology Index
PR Newswire - Tue Dec 16, 7:30AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has been added to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition to the NASDAQ Biotechnology Index will become effective upon market open on December 22, 2014.
ALIM: 5.16 (unch)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Alimera Sciences Announces Closing of $50.0 Million Financing with Deerfield Management
PR Newswire - Mon Dec 15, 7:45AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has closed its offering of Series B Preferred Stock with Deerfield Management and certain of its affiliates (Deerfield). Alimera issued Deerfield an aggregate of 8,291.873 shares of Series B Preferred Stock for a purchase price of $6,030.00 per share, or an aggregate purchase price of approximately $50.0 million. Each share of Series B Preferred Stock is convertible into 1,000 shares of Alimera's common stock at any time at the option of the holder, provided that the holder is prohibited from converting Series B Preferred Stock into shares of Alimera's common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.98% of the total number of shares of Alimera's common stock then issued and outstanding. Alimera also issued an additional 124.378 shares of Series B Preferred Stock to Deerfield as a subscription premium. The Series B Preferred Stock is not redeemable at the option of the holder. The Series B Preferred Stock is not subject to any price-based or other anti-dilution protections and does not provide for any accruing dividends. Except as otherwise required by law (or with respect to approval of certain actions), the Series B Preferred Stock does not have voting rights. Alimera plans to use the proceeds for commercial launch of its lead product, ILUVIEN, in the United States, continued marketing efforts in Europe and general corporate purposes.
ALIM: 5.16 (unch)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Insider Trading Alert - OUTR, ALIM And CINF Traded By Insiders
at The Street - Wed Dec 03, 12:00PM CST
Stocks with insider trader activity include OUTR, ALIM and CINF
CINF: 52.46 (+0.27), ALIM: 5.16 (unch), OUTR: 68.39 (+2.22)
Iluvien cleared in the Netherlands
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 2:28PM CST
ALIM: 5.16 (unch), PSDV: 4.19 (+0.12)
Alimera Sciences' ILUVIEN® Receives Marketing Authorization In The Netherlands For The Treatment Of Chronic Diabetic Macular Edema
PR Newswire - Mon Dec 01, 2:00PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Dutch Inspectie voor de Gezondheidszorg (IGZ) has granted marketing authorization in the Netherlands to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.16 (unch)
Alimera secures new financing
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:57AM CST
ALIM: 5.16 (unch)
Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing
PR Newswire - Fri Nov 28, 7:30AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has entered into a Securities Purchase Agreement with Deerfield Management and certain of its affiliates ("Deerfield"
pursuant to which Alimera will issue shares of preferred stock to Deerfield with an aggregate purchase price of approximately $50.0 million upon the satisfaction of certain closing conditions. Alimera has also agreed to issue an additional 124.378 shares of preferred stock as a subscription premium. The preferred stock will be convertible into an aggregate of 8,416,251 shares of Alimera common stock. Alimera plans to use the proceeds for commercial launch of its lead product, ILUVIEN, in the United States, continued marketing efforts in Europe and general corporate purposes.
ALIM: 5.16 (unch)
Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Ireland For The Treatment Of Chronic Diabetic Macular Edema
PR Newswire - Mon Nov 17, 10:45AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Irish Health Products Regulatory Authority (HPRA) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.16 (unch)
Alimera Sciences wins marketing authorisation in Belgium for ILUVIEN for chronic diabetic macular edema
M2 - Thu Nov 13, 7:08AM CST
Pharmaceutical company Alimera Sciences (NasdaqGM:ALIM) reported on Thursday the receipt of the Belgian Federal Agency for Medicines and Health Products' (FAMHP) marketing approval for ILUVIEN for treating vision impairment with chronic diabetic macular edema (DME) insufficiently responsive to available therapies.
ALIM: 5.16 (unch)
Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Belgium For The Treatment Of Chronic Diabetic Macular Edema
PR Newswire - Wed Nov 12, 6:30AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Belgian Federal Agency for Medicines and Health Products (FAMHP) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.16 (unch)
How it All Plays Out: Research Reports on Align Technology, Alimera, Alkermes, Alliance HealthCare Services, and Allied Healthcare Products
PR Newswire - Tue Feb 03, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Align Technology (NASDAQ: ALGN), Alimera (NASDAQ: ALIM), Alkermes (NASDAQ: ALKS), Alliance HealthCare Services, (NASDAQ: AIQ), and Allied Healthcare Products (NASDAQ: AHPI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ALGN: 56.90 (-0.34), ALIM: 5.16 (unch), AHPI: 1.56 (unch), ALKS: 71.40 (-1.89), AIQ: 24.99 (+0.27)
Alimera Sciences announces marketing approval for ILUVIEN in Finland and Luxembourg under Repeat-Use application procedure
M2 - Tue Jan 27, 3:32AM CST
Pharmaceutical company Alimera Sciences (NasdaqGM:ALIM) revealed on Monday the receipt of marketing authorisation in Finland and Luxembourg for ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.16 (unch)
Alimera Sciences' ILUVIEN® Receives Marketing Authorization in Finland and Luxembourg
PR Newswire - Mon Jan 26, 1:00PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that marketing authorization has been granted by the Finnish Medicines Agency in Finland and the Ministry of Health in Luxembourg to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.16 (unch)
Alimera Continues To Fly Under Radar As ILUVIEN Launch In U.S. Approaches
Gary Bourgeault - at Seeking Alpha - Sat Jan 17, 11:51AM CST
ALIM: 5.16 (unch)
Iluvien sales commence in Portugal
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 11:35AM CST
ALIM: 5.16 (unch), PSDV: 4.19 (+0.12)
Alimera Sciences Announces First Sale of ILUVIEN® in Portugal
PR Newswire - Wed Jan 14, 10:48AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals today announced that the first unit of ILUVIEN® has been sold in Portugal for the treatment of vision impairment associated with chronic diabetic macular edema insufficiently responsive to available treatments. Portugal is the third country in which ILUVIEN is now commercially available.
ALIM: 5.16 (unch)
NEA Names Frank Torti and Rick Yang Partners; Aaron Jacobson Promoted to Principal
PR Newswire - Tue Jan 13, 3:17PM CST
New Enterprise Associates, Inc. (NEA), a global venture capital firm, today announced the promotions of three members of its investing team: Frank Torti, M.D., to Partner; Rick Yang to Partner; and Aaron Jacobson to Principal.
ALIM: 5.16 (unch)
Insider Trading Alert - TESO, ALIM And NUAN Traded By Insiders
at The Street - Wed Jan 07, 10:45AM CST
Stocks with insider trader activity include TESO, ALIM and NUAN
ALIM: 5.16 (unch), NUAN: 14.26 (+0.20), TESO: 11.37 (+0.37)
Alimera Sciences Added to NASDAQ Biotechnology Index
PR Newswire - Tue Dec 16, 7:30AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has been added to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition to the NASDAQ Biotechnology Index will become effective upon market open on December 22, 2014.
ALIM: 5.16 (unch)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Alimera Sciences Announces Closing of $50.0 Million Financing with Deerfield Management
PR Newswire - Mon Dec 15, 7:45AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has closed its offering of Series B Preferred Stock with Deerfield Management and certain of its affiliates (Deerfield). Alimera issued Deerfield an aggregate of 8,291.873 shares of Series B Preferred Stock for a purchase price of $6,030.00 per share, or an aggregate purchase price of approximately $50.0 million. Each share of Series B Preferred Stock is convertible into 1,000 shares of Alimera's common stock at any time at the option of the holder, provided that the holder is prohibited from converting Series B Preferred Stock into shares of Alimera's common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.98% of the total number of shares of Alimera's common stock then issued and outstanding. Alimera also issued an additional 124.378 shares of Series B Preferred Stock to Deerfield as a subscription premium. The Series B Preferred Stock is not redeemable at the option of the holder. The Series B Preferred Stock is not subject to any price-based or other anti-dilution protections and does not provide for any accruing dividends. Except as otherwise required by law (or with respect to approval of certain actions), the Series B Preferred Stock does not have voting rights. Alimera plans to use the proceeds for commercial launch of its lead product, ILUVIEN, in the United States, continued marketing efforts in Europe and general corporate purposes.
ALIM: 5.16 (unch)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Insider Trading Alert - OUTR, ALIM And CINF Traded By Insiders
at The Street - Wed Dec 03, 12:00PM CST
Stocks with insider trader activity include OUTR, ALIM and CINF
CINF: 52.46 (+0.27), ALIM: 5.16 (unch), OUTR: 68.39 (+2.22)
Iluvien cleared in the Netherlands
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 2:28PM CST
ALIM: 5.16 (unch), PSDV: 4.19 (+0.12)
Alimera Sciences' ILUVIEN® Receives Marketing Authorization In The Netherlands For The Treatment Of Chronic Diabetic Macular Edema
PR Newswire - Mon Dec 01, 2:00PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Dutch Inspectie voor de Gezondheidszorg (IGZ) has granted marketing authorization in the Netherlands to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.16 (unch)
Alimera secures new financing
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:57AM CST
ALIM: 5.16 (unch)
Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing
PR Newswire - Fri Nov 28, 7:30AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has entered into a Securities Purchase Agreement with Deerfield Management and certain of its affiliates ("Deerfield"
pursuant to which Alimera will issue shares of preferred stock to Deerfield with an aggregate purchase price of approximately $50.0 million upon the satisfaction of certain closing conditions. Alimera has also agreed to issue an additional 124.378 shares of preferred stock as a subscription premium. The preferred stock will be convertible into an aggregate of 8,416,251 shares of Alimera common stock. Alimera plans to use the proceeds for commercial launch of its lead product, ILUVIEN, in the United States, continued marketing efforts in Europe and general corporate purposes. ALIM: 5.16 (unch)
Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Ireland For The Treatment Of Chronic Diabetic Macular Edema
PR Newswire - Mon Nov 17, 10:45AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Irish Health Products Regulatory Authority (HPRA) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.16 (unch)
Alimera Sciences wins marketing authorisation in Belgium for ILUVIEN for chronic diabetic macular edema
M2 - Thu Nov 13, 7:08AM CST
Pharmaceutical company Alimera Sciences (NasdaqGM:ALIM) reported on Thursday the receipt of the Belgian Federal Agency for Medicines and Health Products' (FAMHP) marketing approval for ILUVIEN for treating vision impairment with chronic diabetic macular edema (DME) insufficiently responsive to available therapies.
ALIM: 5.16 (unch)
Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Belgium For The Treatment Of Chronic Diabetic Macular Edema
PR Newswire - Wed Nov 12, 6:30AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Belgian Federal Agency for Medicines and Health Products (FAMHP) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.16 (unch)
